Minoryx Therapeutics, a CataloniaBio & HealthTech member, and Sperogenix Therapeutics entered into an exclusive license agreement for the development and commercialization of MIN-102 for the treatment of X-linked adrenoleukodystrophy (X-ALD) in China, Hong Kong and Macau. Currently, there is no treatment for X-ALD.

Under the terms of the agreement, Minoryx will receive an initial upfront payment and pre-defined regulatory and commercial milestone payments of up to €66-million, as well as double-digit royalties on annual net sales.

Marc Martinell, co-founder and CEO of Minoryx, says that "Sperogenix is a company with experience and capabilities in the field of rare diseases in China, which make us highly confident in our partnership. Martinell also points out that this is Minoryx's first license: “This is a major milestone that under scores the potential of leriglitazone to address an important unmet medical need.” 

Minoryx is backed by a syndicate of experienced investors, which includes Ysios Capital, HealthEquity, Roche Venture Fund, Kurma Partners, among others.

More information

You also may be interested in:

• Minoryx begins a phase II clinical trial with leriglitazone for the treatment of cALD
• Friedreich’s Ataxia treatment of Minoryx receives the orphan drug designation by FDA and EMA
• Minoryx Therapeutics extends its activities in Belgium
• Minoryx raises € 21.3 million in Series B funding round